

Addition of orlistat benefits obese patients with T2DM

September 17 2015



(HealthDay)—In overweight and obese patients with type 2 diabetes (T2D), treatment with orlistat in addition to lifestyle modifications improves outcomes, according to research published online Sept. 8 in *Obesity Reviews*.

N.M. Aldekhail, of the University of Glasgow in the United Kingdom, and colleagues conducted a systematic review of [randomized controlled trials](#) of orlistat in participants with a [body mass index](#) of 25 kg/m² or higher who were diagnosed with T2D. A meta-analysis was performed on the data from 12 studies to examine the effects of orlistat on glycemic control.

The researchers found that the overall mean weight reduction at three,

six, and 12 months in the orlistat group was -4.25 kg. The mean weight difference between the orlistat group and the control group was -2.1 kg, the mean HbA1c difference was -6.12 mmol mol⁻¹, and the mean fasting blood glucose difference was -1.16 mmol L⁻¹.

"Treatment with orlistat plus lifestyle intervention resulted in significantly greater weight loss and improved [glycemic control](#) in overweight and [obese patients](#) with type 2 diabetes compared with lifestyle intervention alone," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Addition of orlistat benefits obese patients with T2DM (2015, September 17) retrieved 3 May 2024 from
<https://medicalxpress.com/news/2015-09-addition-orlistat-benefits-obese-patients.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--